Total Payments
$387,089
2024 Payments
$112,229
Companies
24
Transactions
587
Medicare Patients
391
Medicare Billing
$30,988
Payment Breakdown by Category
Other$262,285 (67.8%)
Travel$86,662 (22.4%)
Consulting$20,421 (5.3%)
Food & Beverage$17,402 (4.5%)
Education$318.96 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $243,895 | 141 | 63.0% |
| Travel and Lodging | $86,662 | 155 | 22.4% |
| Consulting Fee | $20,421 | 15 | 5.3% |
| Food and Beverage | $17,402 | 248 | 4.5% |
| Honoraria | $16,465 | 20 | 4.3% |
| Grant | $1,175 | 2 | 0.3% |
| Compensation for serving as faculty or as a speaker for a medical education program | $750.00 | 2 | 0.2% |
| Education | $318.96 | 4 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Biotech, Inc. | $180,790 | 219 | $0 (2024) |
| GENZYME CORPORATION | $63,834 | 106 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $60,698 | 77 | $0 (2024) |
| GlaxoSmithKline, LLC. | $27,171 | 29 | $0 (2022) |
| Karyopharm Therapeutics Inc. | $25,050 | 68 | $0 (2024) |
| Adaptive Biotechnologies Corporation | $11,064 | 15 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $6,605 | 12 | $0 (2023) |
| Amgen Inc. | $5,872 | 10 | $0 (2023) |
| Celgene Corporation | $4,154 | 28 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $937.70 | 4 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $112,229 | 175 | Janssen Biotech, Inc. ($70,116) |
| 2023 | $84,740 | 145 | Janssen Biotech, Inc. ($50,030) |
| 2022 | $121,251 | 156 | Janssen Biotech, Inc. ($37,113) |
| 2021 | $68,869 | 111 | Janssen Biotech, Inc. ($23,531) |
All Payment Transactions
587 individual payment records from CMS Open Payments — Page 1 of 24
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,815.00 | General |
| Category: Oncology | ||||||
| 12/16/2024 | PFIZER INC. | ELREXFIO (Drug) | Food and Beverage | In-kind items and services | $14.54 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $952.00 | General |
| Category: Oncology | ||||||
| 12/08/2024 | Janssen Biotech, Inc. | TALVEY (Biological), TECVAYLI | Food and Beverage | In-kind items and services | $41.71 | General |
| Category: Oncology | ||||||
| 12/08/2024 | Janssen Biotech, Inc. | TALVEY (Biological) | Food and Beverage | In-kind items and services | $22.19 | General |
| Category: Oncology | ||||||
| 12/07/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $127.15 | General |
| Category: Oncology | ||||||
| 12/07/2024 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $75.53 | General |
| Category: Oncology | ||||||
| 12/05/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Travel and Lodging | In-kind items and services | $200.67 | General |
| Category: Oncology | ||||||
| 12/05/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Travel and Lodging | In-kind items and services | $2.00 | General |
| Category: Oncology | ||||||
| 12/04/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Travel and Lodging | In-kind items and services | $576.49 | General |
| Category: Oncology | ||||||
| 12/04/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Food and Beverage | In-kind items and services | $33.25 | General |
| Category: Oncology | ||||||
| 11/20/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,815.00 | General |
| Category: Oncology | ||||||
| 11/20/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,768.00 | General |
| Category: Oncology | ||||||
| 11/20/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,410.00 | General |
| Category: Oncology | ||||||
| 11/20/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Travel and Lodging | In-kind items and services | $479.90 | General |
| Category: Oncology | ||||||
| 11/20/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $148.15 | General |
| Category: Oncology | ||||||
| 11/20/2024 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $32.66 | General |
| Category: ONCOLOGY | ||||||
| 11/19/2024 | Janssen Scientific Affairs, LLC | — | Consulting Fee | Cash or cash equivalent | $580.00 | General |
| 11/19/2024 | Janssen Scientific Affairs, LLC | — | Food and Beverage | In-kind items and services | $147.68 | General |
| 11/19/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $33.81 | General |
| Category: Oncology | ||||||
| 11/19/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $18.75 | General |
| Category: Oncology | ||||||
| 11/15/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Travel and Lodging | In-kind items and services | $748.61 | General |
| Category: Oncology | ||||||
| 11/15/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Food and Beverage | In-kind items and services | $48.49 | General |
| 11/13/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Consulting Fee | Cash or cash equivalent | $1,956.00 | General |
| Category: Oncology | ||||||
| 11/13/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $149.60 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 142 | 215 | $62,790 | $13,324 |
| 2022 | 2 | 141 | 208 | $55,730 | $12,039 |
| 2021 | 3 | 76 | 97 | $18,360 | $4,656 |
| 2020 | 2 | 32 | 34 | $5,100 | $968.82 |
Total Patients
391
Total Services
554
Medicare Billing
$30,988
Procedure Codes
13
All Medicare Procedures & Services
13 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 56 | 91 | $28,210 | $6,509 | 23.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 40 | 62 | $12,400 | $2,964 | 23.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 25 | 30 | $12,900 | $2,264 | 17.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 21 | 32 | $9,280 | $1,587 | 17.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 41 | 61 | $18,910 | $4,719 | 25.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 58 | 91 | $18,200 | $4,394 | 24.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 27 | 39 | $11,310 | $1,747 | 15.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 15 | 17 | $7,310 | $1,179 | 16.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 30 | 39 | $7,800 | $1,986 | 25.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 19 | 21 | $6,510 | $1,689 | 25.9% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Facility | 2021 | 27 | 37 | $4,050 | $981.27 | 24.2% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 16 | 17 | $3,400 | $653.52 | 19.2% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Facility | 2020 | 16 | 17 | $1,700 | $315.30 | 18.5% |
About Daniel Verina, NP
Daniel Verina, NP is a Acute Care healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/17/2010. The National Provider Identifier (NPI) number assigned to this provider is 1083929897.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Daniel Verina, NP has received a total of $387,089 in payments from pharmaceutical and medical device companies, with $112,229 received in 2024. These payments were reported across 587 transactions from 24 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($243,895).
As a Medicare-enrolled provider, Verina has provided services to 391 Medicare beneficiaries, totaling 554 services with total Medicare billing of $30,988. Data is available for 4 years (2020–2023), covering 13 distinct procedure/service records.
Ad
Practice Information
- Specialty Acute Care
- Location New York, NY
- Active Since 08/17/2010
- Last Updated 12/06/2013
- Taxonomy Code 363LA2100X
- Entity Type Individual
- NPI Number 1083929897
Products in Payments
- DARZALEX (Biological) $144,850
- SARCLISA (Biological) $62,554
- NINLARO (Drug) $60,481
- TECVAYLI (Biological) $32,393
- BLENREP (Biological) $27,171
- XPOVIO (Drug) $25,050
- clonoSEQ (Device) $11,064
- Pomalyst (Drug) $6,416
- Kyprolis (Drug) $4,608
- ABECMA (Biological) $144.71
- CARVYKTI (Biological) $126.07
- BRUKINSA (Drug) $125.00
- ELZONRIS (Drug) $122.44
- ELITEK (Biological) $105.04
- Epkinly (Drug) $93.06
- TALVEY (Biological) $88.03
- CARVYKTI (Drug) $85.07
- Revlimid (Drug) $70.66
- KEYTRUDA (Biological) $69.32
- IMBRUVICA (Drug) $32.22
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Acute Care Doctors in New York
Mrs. Katie Worthington, Agacnp-Bc, AGACNP-BC
Acute Care — Payments: $15,737
Acute Care $15,737
Julia Cereda, Agacnp-Bc, AGACNP-BC
Acute Care — Payments: $9,648
Acute Care $9,648
Julie Anne Roldan
Acute Care — Payments: $8,351
Acute Care $8,351
Ms. Kristen Donchez, Acnpc-Ag, ACNPC-AG
Acute Care — Payments: $7,847
Acute Care $7,847
Kathryn Ciccolini, Agacnp-Bc, AGACNP-BC
Acute Care — Payments: $6,069
Acute Care $6,069
Mrs. Audrey Kleet, Acnp-Bc, ACNP-BC
Acute Care — Payments: $5,921
Acute Care $5,921